Funder: Breakthrough T1D

Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal)

Funding Amounts: Up to $3,000,000 total over 3 years per award; budget must align with project scope.

Summary: Supports clinical trials to advance therapies for cardiovascular disease in people with type 1 diabetes, aiming to improve prevention, diagnosis, and treatment.

Key Information: LOI approval is required before submitting a full proposal; both academic and industry applicants are eligible.